Patents Examined by Sun Jae Yoo
-
Patent number: 11976072Abstract: The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.Type: GrantFiled: June 21, 2022Date of Patent: May 7, 2024Assignee: Gilead Sciences, Inc.Inventors: Julian A. Codelli, Michael Graupe, Juan A. Guerrero, Stephen D. Holmbo, Tetsuya Kobayashi, Yasamin Moazami, Leena B. Patel, Heath A. Weaver, Jie Xu, Suet C. Yeung, QingMing Zhu
-
Patent number: 11976060Abstract: The present invention relates to a method for preparing a ?-lactam derivative, wherein a substituted N-quinoline-3-butenamide derivative is used as a substrate to react with a toluene derivative or a heterocyclic derivative at 90-150° C. in the presence of DTBP and a copper salt catalyst, to prepare a ?-lactam derivative. According to the method of the present invention, a variety of ?-lactam derivatives can be obtained with a high yield. The reaction of the present invention has mild reaction conditions, and simple reaction operation and post-treatment process, and is suitable for large-scale production.Type: GrantFiled: September 4, 2019Date of Patent: May 7, 2024Assignee: SOOCHOW UNIVERSITYInventors: Runsheng Zeng, Peng Shi, Yingsheng Zhao
-
Patent number: 11970463Abstract: The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R1, R2A, R2B, R2C, R2D, W, X, Y, and Z have the meanings defined herein. Such compounds are useful in inhibiting NLRP3 inflammasome activity and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions in which the NLRP3 inflammasome is implicated. The specification further relates to compositions comprising such compounds.Type: GrantFiled: July 1, 2022Date of Patent: April 30, 2024Assignees: AstraZeneca AB, Mitsubishi Tanabe Pharma CorporationInventors: Lars Anders Mikael Johansson, Giulia Bergonzini, Henrik Gradén, Hiroshi Sugama, Takehiko Matsumura
-
Patent number: 11969420Abstract: The present invention includes methods for treating a proliferative disorder comprising administering a therapeutically effective amount of crenolanib or a salt thereof in combination with pharmaceutical agent targeting apoptosis pathway proteins wherein the crenolanib and other agent are provided at least one of sequentially or concomitantly in a subject for use in the treatment of the proliferative disease, wherein the subject is a human subject.Type: GrantFiled: May 14, 2021Date of Patent: April 30, 2024Assignee: AROG PHARMACEUTICALS, INC.Inventor: Vinay K. Jain
-
Patent number: 11969418Abstract: This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular Bruton tyrosine kinase (“BTK”) inhibitors for treatment of subjects with relapsing multiple sclerosis.Type: GrantFiled: January 19, 2021Date of Patent: April 30, 2024Assignee: GENZYME CORPORATIONInventors: Meehyung Cho, Timothy J. Turner, Erik Wallstroem
-
Patent number: 11970498Abstract: The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.Type: GrantFiled: February 8, 2023Date of Patent: April 30, 2024Assignee: BLUEPRINT MEDICINES CORPORATIONInventors: Douglas Wilson, Neil Bifulco, Jr., Natasja Brooijmans, Joseph L. Kim, Philip D. Ramsden, Richard Vargas, Steven Mark Wenglowsky
-
Patent number: 11964943Abstract: 3,5-Diarylidenyl-N-substituted-piperid-4-one analogs, and pharmaceutically acceptable derivatives thereof, are useful in the treatment or prevention of disorders including cancer, autoimmune disorders, inflammatory disorders, and fibrotic disorders. The compounds are included in pharmaceutical compositions, and are useful for treating disorders, such as cancer associated with aberrant Stat3 pathway activity. The compositions further include another therapeutic agent, such as an anticancer drug. Such compounds or compositions thereof are used to treat resistant and/or metastatic cancers. Methods also inhibit Stat3 pathway activity in a cell. Other methods are useful for making the pharmaceutical compounds. Synthetic methods are also useful for making the compounds. The compounds and compositions are useful as a fluorescent probe.Type: GrantFiled: May 19, 2020Date of Patent: April 23, 2024Inventors: Konstantinos Kiakos, John A. Hartley, Moses Namfong Lee
-
Patent number: 11964972Abstract: Ditosylate salts of N2-(2-ethoxy-4-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-6-methyl-N8-neopentylpyrido[3,4-d]pyrimidine-2,8-diamine, and crystalline forms thereof; processes for the preparation of the new salt forms; and their use as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer.Type: GrantFiled: June 6, 2019Date of Patent: April 23, 2024Assignee: CRT Pioneer Fund LPInventors: Julian S. Northen, John Mykytiuk, Gillian Moore
-
Patent number: 11958809Abstract: Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.Type: GrantFiled: September 24, 2021Date of Patent: April 16, 2024Assignee: CYTOKINETICS, INC.Inventors: Sheng Cui, Henry Morrison, Karthik Nagapudi, Shawn D. Walker, Charles Bernard, Karl Bennett Hansen, Neil Fred Langille, Alan Martin Allgeier, Steven M. Mennen, Jacqueline C. S. Woo, Bradley Paul Morgan, Alex Muci
-
Patent number: 11958833Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the Invention include compounds having the formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c, R1d, R1e, R1f, R1g, R2, X, L and A are as defined herein.Type: GrantFiled: August 16, 2021Date of Patent: April 16, 2024Assignee: Mission Therapeutics LimitedInventors: Mark Ian Kemp, Martin Lee Stockley, Andrew Madin
-
Patent number: 11963439Abstract: The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the compound according to the present disclosure, it is possible to produce an organic electroluminescent device having improved driving voltage, power efficiency, and/or lifetime properties compared to the conventional organic electroluminescent devices.Type: GrantFiled: August 24, 2022Date of Patent: April 16, 2024Assignee: Rohm and Haas Electronic Materials Korea Ltd.Inventors: Eun-Joung Choi, Young-Kwang Kim, Su-Hyun Lee, So-Young Jung, YeJin Jeon, Hong-Se Oh, Dong-Hyung Lee, Jin-Man Kim, Hyun-Woo Kang, Mi-Ja Lee, Hee-Ryong Kang, Hyo-Nim Shin, Jeong-Hwan Jeon, Sang-Hee Cho
-
Patent number: 11952353Abstract: Compounds that inhibit the activity of Signal transducer and activator of transcription 3 (STAT3), or pharmaceutically acceptable salts or prodrugs thereof, and methods of using these compounds to treat cancer and other diseases.Type: GrantFiled: December 6, 2019Date of Patent: April 9, 2024Assignee: The Regents of the University of ColoradoInventors: Philip Reigan, Donald S. Backos, Christopher J. Matheson, Steffanie L. Furtek, Craig T. Jordan, Maria L. Amaya
-
Patent number: 11939343Abstract: The present disclosure relates to STING (Stimulator of Interferon Genes) agonist compounds, methods of making the compounds and their methods of use.Type: GrantFiled: September 9, 2021Date of Patent: March 26, 2024Assignee: Mersana Therapeutics, Inc.Inventors: Jeremy R. Duvall, Keith W. Bentley, Brian D. Jones, Eugene W. Kelleher, Soumya S. Ray, Joshua D. Thomas, Dorin Toader
-
Patent number: 11932648Abstract: The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.Type: GrantFiled: June 27, 2022Date of Patent: March 19, 2024Assignee: BLUEPRINT MEDICINES CORPORATIONInventors: Douglas Wilson, Neil Bifulco, Jr., Natasja Brooijmans, Joseph L. Kim, Emanuele Perola, Philip D. Ramsden, Richard Vargas, Steven Mark Wenglowsky
-
Patent number: 11925606Abstract: The invention discloses a composition comprising not less than 20% w/w bisdemethoxycurcumin for regeneration of alveolar cells damaged in emphysematous conditions and for the therapeutic management of chronic obstructive pulmonary disease and acute respiratory distress syndrome. The composition further comprises 10-35% w/w demethoxycurcumin and 10-45% w/w curcumin. The composition is very suitable for treating COPD and ARDS due to viral infections, specifically COVID 19 and for improving lung function during prognosis.Type: GrantFiled: January 16, 2021Date of Patent: March 12, 2024Assignee: SAMI-SABINSA GROUP LIMITEDInventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sarang Bani, Anjali Pandey
-
Patent number: 11925617Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.Type: GrantFiled: February 26, 2021Date of Patent: March 12, 2024Assignees: NORTHROP GRUMMAN SYSTEMS, CORPORATION and EPICENTRX, INC.Inventors: Mark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
-
Patent number: 11919884Abstract: A method for preparing voriconazole L-camphorsulphonate and voriconazole. The method for preparing voriconazole L-camphorsulphonate comprises: method 1: dissolving (2R,3S)/(2S,3R) isomer mixture and L-camphor sulphonic acid in water and acetone, and performing crystallisation filtration to obtain voriconazole L-camphorsulphonate; method 2: (a) dissolving a mixture of isomer mixture and L-camphor sulphonic acid in a first solvent and then performing crystallisation filtration; or (a?) dissolving L-camphorsulphonate of the isomer mixture in a first solvent and then performing crystallisation filtration; (b) concentrating the filtrate obtained in step (a) or (a?) into a solid; and (c) dissolving the solid obtained in step (b) in a second solvent and performing crystallisation filtration to obtain voriconazole L-camphorsulphonate. Adjusting the resolution solvent effectively reduces production costs and facilitates recycling of the resolution solvent.Type: GrantFiled: November 10, 2016Date of Patent: March 5, 2024Assignee: Zhejiang Huahai Pharmaceutical Co., Ltd.Inventors: Hu Huang, Wenfeng Huang, Guoliang Tu, Zhongming Xu, Qianghui Wu, Zhaoyang Meng, Yuling Fang
-
Patent number: 11918584Abstract: The present invention provides combination therapy that includes an KRASG12C inhibitor, such as or a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.Type: GrantFiled: July 21, 2022Date of Patent: March 5, 2024Assignee: Amgen Inc.Inventors: James Russell Lipford, Jude Robert Canon, Anne Y. Saiki, Karen Louise Rex
-
Patent number: 11911376Abstract: Methods of treating, reducing the risk of, preventing, or alleviating at least one symptom of a retinal disease, injury, or condition in a subject involve administering a pharmaceutically effective amount of kynurenic acid to the subject. The kynurenic acid may be administered intravenously or intravitreally. Systems for treating retinal diseases, injuries, or conditions are also disclosed and may include an administration device.Type: GrantFiled: March 12, 2021Date of Patent: February 27, 2024Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADOInventors: Ram H. Nagaraj, Rooban B. Nahomi, Mi-hyun Nam
-
Patent number: 11903907Abstract: The invention provides a soluble honokiol derivative (such as a water soluble honokiol derivative) and its application in antagonizing glycoprotein VI receptor and providing antioxidant and neuroprotective effects.Type: GrantFiled: July 17, 2020Date of Patent: February 20, 2024Assignees: TAIPEI MEDICAL UNIVERSITY, CATHAY GENERAL HOSPITALInventors: Joen-Rong Sheu, Fa-Kung Lee, Chih-Cheng Chien, Chih-Ming Ho, Chao-Chien Chang, Cheng-Ying Hsieh, Jing-Ping Liou